Ruthenium red attenuates acute pancreatitis by inhibiting MCU and improving mitochondrial function

Biochem Biophys Res Commun. 2022 Dec 20:635:236-243. doi: 10.1016/j.bbrc.2022.10.044. Epub 2022 Oct 14.

Abstract

Acute pancreatitis (AP) is a common inflammatory disease of the digestive system. Mitochondrial calcium uniporter (MCU) mediates mitochondrial uptake of Ca2+ and plays an important role in calcium homeostasis. However, it is undefined whether AP can be relieved by inhibiting MCU. This study aimed to study the therapeutic potential of Ruthenium red (RuR), a MCU inhibitor, in AP mice model and primary acinar cells. Cell injury and AP mice model was induced by caerulein. RuR alleviated CER-AP evidenced by reduced serum lipase, TNF-α, and pancreatic MPO levels, less severe pancreatic pathology damage, and decreased inflammatory cell infiltration. In freshly isolated pancreatic acinar cells, RuR diminished cell necrosis with effect on suppressing the expression of MCU. RuR also decreased levels of cytosolic calcium and ROS, preventing mitochondrial membrane potential loss, ATP depletion and MPTP opening. The present findings indicate that inhibit MCU by RuR has a beneficial effect in AP by preventing calcium overload, mitochondrial dysfunction, and cell necrosis.

Keywords: Acute pancreatitis; Mitochondrial calcium uniporter; Mitochondrial dysfunction; Necrosis; Ruthenium red.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Animals
  • Calcium Channel Blockers* / therapeutic use
  • Calcium* / metabolism
  • Mice
  • Mitochondria / metabolism
  • Necrosis / pathology
  • Pancreatitis* / drug therapy
  • Pancreatitis* / pathology
  • Ruthenium Red* / therapeutic use

Substances

  • Calcium
  • mitochondrial calcium uniporter
  • Ruthenium Red
  • Calcium Channel Blockers